IP
50
3
ZION
59
3
AME
48
3
CCL
50
3
T
62
5
SO
64
5
OKE
52
2
BIIB
39
3
R
65
2
XOM
42
2
ICE
62
7
URI
53
7
OMC
42
2
SYY
47
4
HPE
21
3
ROST
65
4
RF
58
2
EA
50
4
HP
28
2
AVGO
52
-2
IP
50
3
ZION
59
3
AME
48
3
CCL
50
3
T
62
5
SO
64
5
OKE
52
2
BIIB
39
3
R
65
2
XOM
42
2
ICE
62
7
URI
53
7
OMC
42
2
SYY
47
4
HPE
21
3
ROST
65
4
RF
58
2
EA
50
4
HP
28
2
AVGO
52
-2
Financhill
Back

Intellia Therapeutics 10K Form

Sell
19

NTLA
Intellia Therapeutics

Last Price:
$7.35
Seasonality Move:
35.35%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NTLA News And Ratings

See the #1 stock for the next 7 days that we like better than NTLA

NTLA Financial Statistics

Sales & Book Value

Annual Sales: $57.9M
Cash Flow: $-86.2M
Price / Cash Flow: 0
Annual Sales: $8.55
Price / Book: 0.89

Profitability

EPS (TTM): -5.25000
Net Income (TTM): $-519M
Gross Margin: --
Return on Equity: -53.05%
Return on Assets: -42.43%

Intellia Therapeutics Earnings Forecast

Key Intellia Therapeutics Financial Ratios

  • The Research & Development expenses have been 805.69% of Revenue.
  • The Net Earning history of NTLA is -896.77% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 2 years.

Intellia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: NTLA
CUSIP: 45826J
Website: intelliatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.77
Quick Ratio: 5.5

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NTLA Technical Analysis vs Fundamental Analysis

Sell
19
Intellia Therapeutics (NTLA) is a Sell

Is Intellia Therapeutics a Buy or a Sell?